Targeted conditioning with iodine (131I) apamistamab enabled older patients with relapsed or refractory acute myeloid leukemia to undergo allogeneic hematopoietic stem cell transplantation, according to results of the phase 3 SIERRA trial.
The findings, presented at 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, showed iodine (131I) apamistamab, known as Iomab-B (Actinium Pharmaceuticals), led to rapid engraftment and durable complete remissions vs. conventional care, with low incidence of serious adverse events among a patient population typically